Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis

Accessibility StatementSkip Navigation Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen  Omvoh single-injection dosing will be available for U.S. patients in early 2026 This is the third FDA approval for Omvoh this year, following approvals for Crohn's disease and a citrate-free formulation INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administrat ...